Increased basal intracellular signaling patterns do not correlate with JAK2 genotype in human myeloproliferative neoplasms.
@article{Anand2011IncreasedBI,
title={Increased basal intracellular signaling patterns do not correlate with JAK2 genotype in human myeloproliferative neoplasms.},
author={Shubha Anand and F. Stedham and Emma J Gudgin and Peter J. Campbell and Phillip Beer and Anthony R. Green and Brian J. P. Huntly},
journal={Blood},
year={2011},
volume={118 6},
pages={
1610-21
}
}Myeloproliferative neoplasms (MPNs) are associated with recurrent activating mutations of signaling proteins such as Janus kinase 2 (JAK2). However, the actual downstream signaling events and how these alter myeloid homeostasis are poorly understood. We developed an assay to measure basal levels of phosphorylated signaling intermediates by flow cytometry during myeloid differentiation in MPN patients. Our study provides the first systematic demonstration of specific signaling events and their…
45 Citations
JAK2 inhibitors in the treatment of myeloproliferative neoplasms
- Biology, MedicineExpert opinion on investigational drugs
- 2012
Understanding the intricacies of JAK-STAT pathway activation, including growth factor/cytokine-driven signaling, will open new avenues for therapeutic intervention at known and novel molecular vulnerabilities of MPNs.
AKT is a therapeutic target in myeloproliferative neoplasms
- Biology, MedicineLeukemia
- 2013
Findings establish AKT as a rational therapeutic target in the MPNs by showing that inhibition of PI3K/AKT signaling by MK-2206 affected the growth of both JAK2V617F- or MPLW515L-expressing cells via reduced phosphorylation of AKT and inhibition of its downstream signaling molecules.
Disordered signaling in myeloproliferative neoplasms.
- BiologyHematology/oncology clinics of North America
- 2012
Overview of Transgenic Mouse Models of Myeloproliferative Neoplasms (MPNs)
- BiologyCurrent protocols in pharmacology
- 2017
Early murine model development of JAK2V617F is described, with an analysis of its effects on the hematopoietic stem/progenitor cell niche and interactions with downstream signaling elements and a description of more recent in vivo models developed for evaluating the effect of concomitant mutations in epigenetic modifiers on MPN maintenance and progression.
pSTAT3/pSTAT5 Signaling Patterns in Molecularly Defined Subsets of Myeloproliferative Neoplasms
- BiologyApplied immunohistochemistry & molecular morphology : AIMM
- 2018
The demonstration of distinct STAT staining patterns in molecularly defined MPN suggests that these mutations result in divergent signaling events that may contribute to the biological and prognostic differences in these molecular subsets of MPN.
Constitutive STAT5 phosphorylation in CD34+ cells of patients with primary myelofibrosis: Correlation with driver mutation status and disease severity
- Biology, MedicinePloS one
- 2019
Increased constitutive p-STAT5 and IL6 induced p- STAT3 values in circulating CD34+ cells characterize patients with PMF, pointing toward a complex activation of STAT5-dependent pathways in the stem/progenitor cell compartment, that characterize the phenotypic diversity of PMF.
A novel signalling screen demonstrates that CALR mutations activate essential MAPK signalling and facilitate megakaryocyte differentiation
- BiologyLeukemia
- 2017
Data link aberrant MAPK activation to the MPN phenotype and identify it as a potential therapeutic target in CALR-mutant positive MPNs, a novel strategy that utilizes the full range of kinase selectivity data available from each inhibitor and takes advantage of off-target noise that limits conventional small-interfering RNA or inhibitor screens.
JAK2 mutants (e.g., JAK2V617F) and their importance as drug targets in myeloproliferative neoplasms
- Biology, MedicineJAK-STAT
- 2013
The Janus kinase 2 (JAK2) mutant V617F and other JAK mutants are found in patients with myeloproliferative neoplasms and leukemias and their inhibition by small-molecule kinase inhibitors are discussed.
Targeting glutamine metabolism in myeloproliferative neoplasms.
- Biology, MedicineBlood cells, molecules & diseases
- 2015
References
SHOWING 1-10 OF 34 REFERENCES
Aberrant signal transduction pathways in myeloproliferative neoplasms
- Biology, MedicineLeukemia
- 2008
Recent progress made in deciphering signaling anomalies in PV, ET and PMF is reviewed, with an emphasis on the relationship between JAK2 V617F and cytokine receptor signaling and on cross-talk with several other signaling pathways.
MPLW515L Is a Novel Somatic Activating Mutation in Myelofibrosis with Myeloid Metaplasia
- Biology, MedicinePLoS medicine
- 2006
Activation of JAK-STAT signaling via MPLW515L is an important pathogenetic event in patients with JAK2V617F-negative MF, including extramedullary hematopoiesis, splenomegaly, and megakaryocytic proliferation.
Janus kinase 2 (V617F) mutation status, signal transducer and activator of transcription-3 phosphorylation and impaired neutrophil apoptosis in myelofibrosis with myeloid metaplasia
- Biology, MedicineLeukemia
- 2006
The results suggest that mutant JAK2 contributes to MMM pathogenesis by constitutively phosphorylating STAT3 and diminishing myeloid cell apoptosis.
Single-cell profiling identifies aberrant STAT5 activation in myeloid malignancies with specific clinical and biologic correlates.
- Biology, MedicineCancer cell
- 2008
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.
- Biology, MedicineNature
- 2005
A clonal and recurrent mutation in the JH2 pseudo-kinase domain of the Janus kinase 2 (JAK2) gene in most (> 80%) polycythaemia vera patients leads to constitutive tyrosine phosphorylation activity that promotes cytokine hypersensitivity and induces erythrocytosis in a mouse model.
Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice.
- BiologyBlood
- 2008
Higher levels of JAK2-V617F in mouse bone marrow by retroviral transduction caused a PV-like phenotype without thrombocytosis, consistent with the hypothesis that the ratio of mutant to wild-type JAK1 is critical for the phenotypic manifestation.
The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation.
- BiologyProceedings of the National Academy of Sciences of the United States of America
- 2006
Hematopoietic progenitor assays demonstrated that the differentiation potential of PV was already skewed toward the erythroid lineage at the HSC level, and the aberrant erytroid Potential of PV HSC was potently inhibited with a JAK2 inhibitor, AG490.
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
- Medicine, BiologyThe Lancet
- 2005
Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal
- Medicine, BiologyLeukemia
- 2008
JAK2 and MPL mutations are recurrent in myeloproliferative neoplasms (MPNs). A JAK2 mutation, primarily JAK2V617F, is almost invariably associated with polycythemia vera (PV). However, JAK2V617F also…
JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis.
- Biology, MedicineThe New England journal of medicine
- 2007
Four somatic gain-of-function mutations affecting JAK2 exon 12 define a distinctive myeloproliferative syndrome that affects patients who currently receive a diagnosis of polycythemia vera or idiopathic erythrocytosis.






